Amino acid block modified gadolinium-based contrast agent and application thereof

By replacing the amino acid chunk of the gadolinium magnetic resonance imaging contrast agent, a new gadolinium-based contrast agent with good relaxation rate, low toxicity and stability was designed, and the non-specific distribution of gadolinium-based contrast agent in the prior art was solved and Toxicity problems improve imaging efficiency and stability and have good clinical application prospects.

CN119080875APending Publication Date: 2024-12-06LANZHOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411411501.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-10
Publication Date
2024-12-06

Smart Images

  • Figure BDA0005078122420000021
    Figure BDA0005078122420000021
  • Figure FDA0005078122410000011
    Figure FDA0005078122410000011
  • Figure HDA0005078122430000011
    Figure HDA0005078122430000011
Patent Text Reader

Abstract

The invention discloses an amino acid block modified gadolinium-based contrast agent which is prepared by taking XK (epsilon-DOTA-Gd) X as a template and carrying out amino acid block replacement on two X so as to adjust hydrophilicity. The amino acid chunks are preferably glycine (Gly, G), serine (Ser, S), threonine (Thr, T), tyrosine (Tyr, Y), phenylalanine (Phe, F) or alanine (Ala, A). An in-vitro imaging experiment, a hemolytic activity experiment and a plasma stability experiment show that the synthesized amino acid block modified gadolinium-based contrast agent has good relaxation rate, low toxicity and good stability. Therefore, the amino acid blocking gadolinium-based contrast agent can be used for preparing clinical magnetic resonance imaging diagnostic drugs.
Need to check novelty before this filing date? Find Prior Art